The rise of antibiotic-resistant bacteria poses a growing threat to global public health, rendering once-effective treatments increasingly useless. Recognizing the urgency of the situation, the World Health Organization (WHO) has released new target product profiles (TPPs) designed to guide the development of urgently needed antibiotics. These blueprints outline the desired characteristics for new drugs targeting three critical types of bacterial infections, aiming to streamline the research and development process and prioritize the most pressing needs.
Antimicrobial resistance (AMR) occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to medicines, making infections harder to treat and increasing the risk of disease spread. The WHO’s initiative focuses on infections caused by carbapenem-resistant Enterobacterales, Acinetobacter baumannii, and Pseudomonas aeruginosa – all considered high-priority pathogens. The TPPs address severe antibiotic-resistant gram-positive infections, particularly in patients with weakened immune systems, and community-acquired and healthcare-associated bacterial meningitis. The goal is to incentivize and de-risk antibiotic development, ultimately ensuring a reliable pipeline of innovative and accessible treatments.
Defining the Ideal Antibiotics
Target Product Profiles serve as a roadmap for researchers, funders, and pharmaceutical developers. According to the WHO, these profiles detail the intended use of the antibiotic, the specific patient populations it should target, the desired mechanism of action, and the optimal route of administration. Crucially, they also establish clear benchmarks for quality, safety, efficacy, pharmacokinetics (how the drug moves through the body), access, and affordability. “They are intended to facilitate the most expeditious development of novel antibiotics addressing the greatest and most urgent public health needs posed by antimicrobial resistance (AMR),” the WHO stated.
The development of new antibiotics has not kept pace with the evolving resistance of bacteria. While some progress has been made in recent years, It’s insufficient to address the growing crisis. “The scientific community has developed and approved new antibiotics in recent years. This represents good, but unfortunately not sufficient to catch up with evolving drug-resistance bacteria, especially against those of greatest concern,” explained Yvan Hutin, MD, PhD, director of antimicrobial resistance at the WHO, in a press release. He emphasized the need for a “reliable pipeline with new antibacterial agents that are innovative, affordable, accessible to all those who need them.”
The Challenge of Drug Resistance
The three infection types targeted by the new TPPs are particularly concerning since current treatment options are becoming less effective. The increasing prevalence of drug-resistant bacteria, such as carbapenem-resistant Enterobacterales, poses a significant challenge to healthcare systems worldwide. Research published in Nature highlights the in vitro activity of meropenem-vaborbactam combinations and eravacycline against carbapenem-resistant Acinetobacter baumannii, demonstrating the ongoing search for effective treatments against these resilient pathogens.
Addressing antimicrobial resistance requires a multifaceted approach, including strengthening clinical alliances between human and veterinary medicine. A report in ScienceDirect.com emphasizes the importance of collaboration to tackle global priority antimicrobial-resistant bacterial pathogens, recognizing that resistance can emerge and spread across both human and animal populations.
The WHO’s initiative is part of a broader effort to combat the growing threat of antimicrobial resistance, which is described as an emerging global threat to modern medicine. Reports also indicate a weakness in the global pipeline for new antibiotics and diagnostics, underscoring the need for increased investment and innovation in this critical area.
The development and implementation of these TPPs represent a crucial step towards addressing the urgent need for new antibiotics. Continued research, collaboration, and investment will be essential to ensure a sustainable pipeline of effective treatments and protect global public health from the escalating threat of antimicrobial resistance. The next phase will involve monitoring the progress of antibiotic development programs aligned with these profiles and adapting the TPPs as new scientific evidence emerges.
What are your thoughts on the WHO’s new initiative? Share your comments below, and help spread awareness about the critical issue of antimicrobial resistance.
Disclaimer: This article provides informational content and should not be considered medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
